209 related articles for article (PubMed ID: 19610651)
1. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo.
Kurenova EV; Hunt DL; He D; Magis AT; Ostrov DA; Cance WG
J Med Chem; 2009 Aug; 52(15):4716-24. PubMed ID: 19610651
[TBL] [Abstract][Full Text] [Related]
2. The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
Kurenova E; Liao J; He DH; Hunt D; Yemma M; Bshara W; Seshadri M; Cance WG
Oncotarget; 2013 Oct; 4(10):1632-46. PubMed ID: 24142503
[TBL] [Abstract][Full Text] [Related]
3. A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.
Kurenova E; Ucar D; Liao J; Yemma M; Gogate P; Bshara W; Sunar U; Seshadri M; Hochwald SN; Cance WG
Cell Cycle; 2014; 13(16):2542-53. PubMed ID: 25486195
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.
Stewart JE; Ma X; Megison M; Nabers H; Cance WG; Kurenova EV; Beierle EA
Mol Carcinog; 2015 Jan; 54(1):9-23. PubMed ID: 23868727
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.
Gogate PN; Ethirajan M; Kurenova EV; Magis AT; Pandey RK; Cance WG
Eur J Med Chem; 2014 Jun; 80():154-166. PubMed ID: 24780592
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.
Garces CA; Kurenova EV; Golubovskaya VM; Cance WG
Cancer Res; 2006 Feb; 66(3):1446-54. PubMed ID: 16452200
[TBL] [Abstract][Full Text] [Related]
7. Development of focal adhesion kinase inhibitors in cancer therapy.
Ma WW
Anticancer Agents Med Chem; 2011 Sep; 11(7):638-42. PubMed ID: 21787276
[TBL] [Abstract][Full Text] [Related]
8. A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo.
Golubovskaya VM; Palma NL; Zheng M; Ho B; Magis A; Ostrov D; Cance WG
Anticancer Agents Med Chem; 2013 May; 13(4):532-45. PubMed ID: 22292771
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for insulin-like growth factor I-mediated regulation of focal adhesion kinase.
Kiely PA; Baillie GS; Barrett R; Buckley DA; Adams DR; Houslay MD; O'Connor R
J Biol Chem; 2009 Jul; 284(30):20263-74. PubMed ID: 19423701
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Wendt MK; Schiemann WP
Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.
Beierle EA; Ma X; Stewart JE; Megison M; Cance WG; Kurenova EV
Mol Carcinog; 2014 Mar; 53(3):230-42. PubMed ID: 23065847
[TBL] [Abstract][Full Text] [Related]
12. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.
Walsh C; Tanjoni I; Uryu S; Tomar A; Nam JO; Luo H; Phillips A; Patel N; Kwok C; McMahon G; Stupack DG; Schlaepfer DD
Cancer Biol Ther; 2010 May; 9(10):778-90. PubMed ID: 20234193
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo.
Ucar DA; Magis AT; He DH; Lawrence NJ; Sebti SM; Kurenova E; Zajac-Kaye M; Zhang J; Hochwald SN
Anticancer Agents Med Chem; 2013 May; 13(4):595-602. PubMed ID: 23272972
[TBL] [Abstract][Full Text] [Related]
14. The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer.
Kandil S; Prencipe F; Jones S; Hiscox S; Westwell AD
Chem Biol Drug Des; 2018 Jan; 91(1):314-321. PubMed ID: 28816016
[TBL] [Abstract][Full Text] [Related]
15. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.
Golubovskaya VM; Nyberg C; Zheng M; Kweh F; Magis A; Ostrov D; Cance WG
J Med Chem; 2008 Dec; 51(23):7405-16. PubMed ID: 18989950
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel chloropyramine-cinnamic acid hybrids as potential FAK inhibitors for intervention of metastatic triple-negative breast cancer.
Yang F; Xu K; Zhang S; Zhang J; Qiu Y; Luo J; Tan G; Zou Z; Wang W; Kang F
Bioorg Med Chem; 2022 Jul; 66():116809. PubMed ID: 35569251
[TBL] [Abstract][Full Text] [Related]
17. Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors.
Moen I; Gebre M; Alonso-Camino V; Chen D; Epstein D; McDonald DM
Clin Exp Metastasis; 2015 Dec; 32(8):799-817. PubMed ID: 26445848
[TBL] [Abstract][Full Text] [Related]
18. FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth.
Tancioni I; Miller NL; Uryu S; Lawson C; Jean C; Chen XL; Kleinschmidt EG; Schlaepfer DD
Breast Cancer Res; 2015 Mar; 17():47. PubMed ID: 25880415
[TBL] [Abstract][Full Text] [Related]
19. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
[TBL] [Abstract][Full Text] [Related]
20. Cellular characterization of a novel focal adhesion kinase inhibitor.
Slack-Davis JK; Martin KH; Tilghman RW; Iwanicki M; Ung EJ; Autry C; Luzzio MJ; Cooper B; Kath JC; Roberts WG; Parsons JT
J Biol Chem; 2007 May; 282(20):14845-52. PubMed ID: 17395594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
